Radiation Therapy for Metastatic Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 25
Special Issue Editor
Special Issue Information
Dear Colleagues,
The vast majority of cancer deaths are caused by distant metastases rather than the primary tumor. While early-stage and locally advanced but non-metastatic cancers are generally treated with a curative intent approach incorporating local therapy, pharmaceutical trials for stage IV solid tumors tend to favor a systemic-therapy-alone approach. Despite advances in systemic therapies that have improved median survival for metastatic cancer, a drugs-alone approach only rarely achieves long-term disease-free survival. Radiation therapy, and other local therapies, increasingly plays an important role in improving long-term oncologic outcomes for oligometastases, and can also enhance quality of life for selected patients with polymetastases. While site-specific studies remain valuable, oligometastases could fit into a tumor-agnostic framework that is increasingly accepted in the drug approval and guideline spaces.
The goal of this Special Issue is to highlight the important emerging role of radiation oncology in the basic science, prognosis, treatment, and survivorship of solid tumor metastases, with a special focus on oligometastases.
Dr. Johnny Kao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metastasis
- radiation therapy
- tumor agnostic
- oligometastases
- survivorship
- combined modality therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
